Covagen AG

Covagen specializes in the development of multispecific protein therapeutics through the FynomAb® technology platform. In 2014, Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, acquired Covagen AG for an undisclosed sum, in a deal brokered by the Johnson & Johnson Innovation Center in London. After the acquisition Covagen remained in Schlieren. Later the company moved to Zug where it remains as of 2017.